SCAI and CAIC Announce the Formation of the North American COVID-19 STEMI Registry

April 27, 2020—The Society for Cardiovascular Angiography and Interventions (SCAI) and the Canadian Association of Interventional Cardiology (CAIC) recently announced the formation of the North American COVID-19 ST-segment elevation myocardial infarction (STEMI) Registry (NACMI). The societies believe that this registry has the potential to provide critically important time-sensitive data to inform the management and treatment guidelines applicable to COVID-19 patients.

The NACMI Registry will enroll any COVID-19 positive patients or persons under investigation (PUI) with ST-segment elevation or new-onset left bundle branch block with a clinical correlate of myocardial ischemia (chest pain, dyspnea, cardiac arrest, hemodynamic instability).

The data will be compared with an age- and gender-matched control population from the existing Midwest STEMI Consortium, which is a large (> 15,000), prospective multicenter registry of consecutive STEMI patients.

The study will be chaired by Tim Henry, MD, for SCAI and Payam Dehghani, MD, for CAIC.

The NACMI registry has pending central institutional review board approval and will have an electrocardiogram and angiographic core lab. Interested sites can designate a local principal investigator and contact either Dr. Henry, the SCAI principal investigator, at tim.henry@thechristhospital.com, or Dr. Dehghani, the CAIC principal investigator at pdehghani@me.com. To obtain participating site information, the interested sites should contact the data coordinating center at santiago.garcia@allina.com or ross.garberich@allina.com.